Table 2.

Characteristics of studies not included for meta-analysis (N = 5).

Authors (Year)/ Location	Study Design	Cancer Stages	Samples(N)/ F(%)/ Mean Age [Range]	Primary Regimens	Chemotoxicity Measures	Prevalence of Top Moderate-to-Severe Chemotoxicity Subgroups
Brown et al. (2022) [36]/ USA	P	Colon/ II-III	533/ F56%/ 59 [47–70]	5-FU	Physicians’ chart and progress note review	Discontinuation of chemotherapy (13%)
Cespedes Feliciano et al. (2017) [37]/USA	P	Colon/ II-IV	533/ F55.4%/ 59 [no data]	5-FU	Physicians’ chart and progress note review and EMR ICD9 codes	Early discontinuation (36%)/ Neuropathy (24.1%)
Decoster et al. (2018) [38]/Europe	P	Older Adults mCRC/ IV	252/ F38%/ 77 [69–91]	5-FU	Physicians’ chart and progress note review	Vascular toxicity (35%)/ GI toxicity (13.6%)
Grimes, C. (2022) [42]/ USA	R	CRC/III	89/ F58%/ 62 [no data]	5-FU	Physicians’ chart and progress note review	Diarrhea (6.7%)/ Nausea (5.6%)
Looijaard et al. (2020) [47]/Europe	P	Older Adults Colon/III	53/ F45%/ 71 [68–74]	5-FU	Physicians’ chart and progress note review	Dose reduction/ incompletion (52.8%)

Note: CRC: colorectal cancer; EMR: electronic medical record; F: female; 5-FU: 5-Fluorouracil; GI: gastrointestinal; ICD-9: international classification of diseases, 9th Revision (ICD-9); mCRC: metastasis CRC; and PRO-CTCAE: patient-reported outcomes version of the common terminology criteria for adverse events.